Milestones

Wolfgang Marguerre establishes Octapharma with a single idea: people with haemophilia deserve access to better products.

The first factor VIII medicine, octavi^®, is launched.

Opens first state-of-the-art manufacturing site, acquired from Schwab in Vienna, Austria.

Establishes laboratory in Frankfurt for validation and documentation of virus inactivation methods.

Acquires second manufacturing site from Aventis in Lingolsheim, France, to increase capacity.

Acquires third manufacturing site from Biovitrum in Stockholm, Sweden, to increase product portfolio.

Expands into US market with FDA registration of octagam^®.

Acquires five plasma donation centres in Germany from Deutsche Gesellschaft für Humanplasma.

Octapharma Plasma Inc. founded in the US to operate our own plasma donation centres.

Opens the Institute for Recombinant Protein Research & Development in Heidelberg, Germany, to further invest in innovative therapies.

European Medicines Agency (EMA) approves our first recombinant product for haemophilia A patients, Nuwiq^®.

FDA approves Nuwiq^® for haemophilia A patients in the USA.

panzyga^® receives regulatory approval in Canada and the EU for primary immunodeficiency syndromes and primary immune thrombocytopenia.

Fibryga^® receives marketing authorization for congenital fibrinogen deficiency in 16 EU countries, the US and Canada.

Octapharma announces promising pre-clinical data for SubQ-8, our recombinant FVIII in development for subcutaneous administration.

Our human fibrinogen concentrates receive European label extension to treat acquired fibrinogen deficiency.

The FDA approve the use of octagam® 10% for the treatment of adult dermatomyositis. Other jurisdictions quickly follow, providing a safe, proven treatment option for patients with this rare autoimmune disorder.

European authorities approve the lyophilised presentation of Octapharma’s pooled S/D treated human plasma, octaplasLG®, for transfusion in a pre-hospital setting.